Buprenorphine Hydrochloride

Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2 2026 Net Loss Narrowed Approximately 58% Year-over-Year to Approximately $2.8 Million Commenced Commercial Launch of REZENOPY™, Establishing the Company’s Second Commercial Product and Expanding Its Revenue-Generating Portfolio COMMACK, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and six months ended June 30, 2026. Second Quarter 2026 and First Half 2026 Financial Highlights Revenue increased approximately 510% sequentially to $343,639 in Q2 2026, compared with $56,325 in Q1 2026. First-half 2026 revenue increased significantly year-over-year to $399,964, compared with $10,258 for the first six months of 2025. Q2 2026 gross profit was $335,779, compared to $0 in Q2 2025, with Q2 2026 gross margin being approximately 97.7%. First-half 2026 gross profit increased to $389,629, compared with $673 for the first six months of 2025, with a gross margin of approximately 97.4% for the first half of 2026. Q2 2026 operating expenses decreased approximately 41% year-over-year to approximately $3.0 million, compared with approximately $5.2 million in Q2 2025, demonstrating continued expense management and operating discipline. First-half 2026 operating expenses decreased approximately 24% to about $6.6 million, compared with approximately $8.7 million during the first six months of 2025. Q2 2026 operating loss improved approximately 48% to about $2.7 million, compared with an operating loss of approximately $5.2 million in Q2 2025. Q2 2026 net loss narrowed approximately 58% to about $2.8 million, compared with a net loss of approximately $6.7 million in Q2 2025. Basic and diluted net loss per share improved to $0.07 from $0.48 during that time. First-half 2026 net loss narrowed approximately 36% to about $6.2 million, compared with approximately $9.8 million for the first six months of 2025. Basic and diluted net loss per share improved to $0.16 from $0.83 during that time. As of June 30, 2026, the Company had cash, cash equivalents and restricted cash of approximately $11.2 million compared to approximately $6.7 million of cash and cash equivalents as of December 31, 2025. Key Operational Highlights in Q2 2026 and Subsequent Events: United States Patent and Trademark Office (USPTO) granted a second patent covering REZENOPY ™ (naloxone hydrochloride) Nasal Spray 10 mg, strengthening intellectual property protection for the product through 2041. United States Patent and Trademark Office (USPTO) granted a third patent covering Arbli ™ (losartan potassium) oral suspension, further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041. Secured formulary coverage for REZENOPY ™ with a large national health plan and expanded the commercial team to support market penetration and growth. Expanded ARBLI ™ payer coverage and commercial access, adding approximately 12.5 million covered lives. Commenced the commercial launch of REZENOPY ™ and began fulfillment of initial purchase orders, marking an important milestone in the Company's commercialization strategy. Narasimhan Mani, President, Interim CFO, and Co-CEO of Scienture, commented, “We believe our second-quarter results demonstrate that Scienture has reached an important inflection point. Revenue for Q2 20226 increased about 510% sequentially, from approximately $56,000 in the first quarter to approximately $344,000 in the second quarter. At the same time, we generated gross margins of approximately 98%, reduced operating expenses by about 41% year-over-year and narrowed our net loss by approximately 58%. We also ended the quarter with approximately $11.2 million in cash, cash equivalents and restricted cash, compared with about $6.7 million at year-end 2025, providing us with a stronger financial position as we execute the next phase of our commercial growth strategy. We believe these results demonstrate that we are on the right path to deliver value added business growth in the coming quarters and that we are beginning to realize the operating leverage we have been working toward.” “Arbli’s continued commercial progress gives us confidence in our ability to build and scale differentiated pharmaceutical products, and we believe we have only begun to realize its market opportunity,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We are expanding payer access and commercial availability for Arbli ™ while simultaneously bringing REZENOPY ™ online commercially in the third quarter of 2026. With Arbli ™ continuing to gain traction and REZENOPY ™ becoming our second commercial-stage product, we believe Scienture is positioned to meaningfully accelerate top-line revenue growth during the second half of 2026 and into 2027. With two differentiated FDA-approved products, approximately 98% gross margins, a strengthened cash position and a more disciplined operating expense structure, we believe we have turned an important corner and established a clear path toward our goal of achieving profitability in 2027.” About Arbli ™ Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli ™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli ™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli ™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli ™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook. Arbli ™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli ™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature. INDICATION Arbli ™ is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. IMPORTANT SAFETY INFORMATION Do not take Arbli ™ when pregnant. When pregnancy is detected, discontinue Arbli ™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli ™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Do not co-administer Arbli ™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli ™ in patients with renal impairment (GFR <60 mL/min). Do not administer Arbli ™ in patients with severe hepatic impairment. Arbli ™ has not been studied in patients with severe hepatic impairment. The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917. Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider. About Hypertension Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg. About REZENOPY ™ REZENOPY ™ (naloxone hydrochloride) Nasal Spray 10mg, is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. REZENOPY ™ nasal spray is not a substitute for emergency medical care. If the desired response is not obtained after 2 to 3 minutes, administer a second dose of REZENOPY ™ nasal spray using a new REZENOPY ™ nasal spray device. If there is still no response and additional doses are available, administer additional doses of REZENOPY ™ every 2 to 3 minutes, alternating nostrils and using a new REZENOPY ™ , until emergency medical assistance arrives. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance REZENOPY ™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device. IMPORTANT SAFETY INFORMATION REZENOPY ™ (naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care. Important Safety Information Contraindications: REZENOPY ™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. Warnings and Precautions: Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance. Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required. Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal. Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride. Adverse Reactions: The following adverse reactions were observed in a REZENOPY ™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia. For complete product information, including Patient Information, please refer to the full Prescribing Information. About Scienture Holdings, Inc. SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: and . Cautionary Statements Regarding Forward-Looking Statements This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli™ and REZENOPY™, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law. Contact : SCIENTURE HOLDINGS, INC. 20 Austin Blvd Commack, NY 11725 Email: IR@Scienture.com Scienture Holdings, Inc. formerly TRxADE HEALTH, INC. Condensed Consolidated Balance Sheets As of June 30, 2026 and December 31, 2025 (Unaudited) June 30, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 8,188,140 $ 6,662,008 Accounts receivable, net 385,313 731,328 Inventory 203,074 213,408 Prepaid expenses 425,370 262,278 Deferred offering costs - 47,384 Total current assets 9,201,897 7,916,406 Restricted cash 3,012,271 - Property, plant and equipment, net 14,500 15,500 Notes receivable 5,000,000 5,000,000 Interest receivable 437,500 250,000 Intangible assets, net 70,065,371 70,973,064 Operating lease right-of-use assets 2,468 23,360 Total assets $ 87,734,007 $ 84,178,330 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 916,771 $ 1,443,266 Accrued liabilities 503,634 657,034 Operating lease liability - current 2,546 24,137 Warrant liability - 10,914 Note payable, net of debt discount - current portion 1,118,349 - Development agreement liability - current portion 485,000 600,000 Total current liabilities 3,026,300 2,735,351 Note payable, net of debt discount 9,568,586 - Development agreement liability - 285,000 Deferred tax liability 11,037,595 11,037,595 Total liabilities 23,632,481 14,057,946 Commitments and contingencies (Note 13) Stockholders’ equity: Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 - - Common stock, $0.00001 par value; 100,000,000 shares authorized; 41,064,146 and 40,630,815 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 1,448,331 and 1,015,000 shares unvested as of June 30, 2026 and December 31, 2025, respectively 410 406 Additional paid-in capital 150,876,988 150,671,215 Accumulated deficit (86,775,872 ) (80,551,237 ) Total stockholders’ equity 64,101,526 70,120,384 Total liabilities and stockholders’ equity $ 87,734,007 $ 84,178,330 Scienture Holdings, Inc. formerly TRxADE HEALTH, INC. Condensed Consolidated Statements Of Operations For the Three and Six Months Ended June 30, 2026 and 2025 (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 Revenues $ 343,639 $ - $ 399,964 $ 10,258 Cost of sales 7,860 - 10,335 9,585 Gross profit 335,779 - 389,629 673 Operating expenses: Wage and salary expense 411,411 773,739 831,419 1,469,807 Professional fees 963,752 209,763 1,896,304 622,613 Accounting and legal expense 117,815 381,683 443,993 852,508 Technology expense 7,139 21,408 22,902 83,028 General and administrative 368,790 2,927,764 1,443,654 4,283,712 Research and development 1,166,605 843,549 1,960,589 1,418,228 Total operating expenses 3,035,512 5,157,906 6,598,861 8,729,896 Operating loss (2,699,733 ) (5,157,906 ) (6,209,232 ) (8,729,223 ) Non-operating income (expense): Change in fair value of warrant liability - 76,122 10,910 722,108 Change in fair value of derivative liability - (662,916 ) - (59,594 ) Loss on conversion of note payable - - - (96,646 ) Loss on disposition of subsidiaries - (385,528 ) - (385,528 ) Interest income 147,147 63,148 280,491 88,590 Interest expense (269,785 ) (653,493 ) (306,804 ) (1,324,277 ) Total non-operating expense (122,638 ) (1,562,667 ) (15,403 ) (1,055,347 ) Benefit (provision) for income taxes - - - - Net loss $ (2,822,371 ) $ (6,720,573 ) $ (6,224,635 ) $ (9,784,570 ) Net loss per common share Basic $ (0.07 ) $ (0.48 ) $ (0.16 ) $ (0.83 ) Diluted $ (0.07 ) $ (0.48 ) $ (0.16 ) $ (0.83 ) Weighted average common shares outstanding Basic 39,615,815 14,141,443 39,615,815 11,844,024 Diluted 39,615,815 14,141,443 39,615,815 11,844,024

– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today reported its financial results for the quarter ended June 30, 2026, and provided a business update. “In the second quarter, we saw strong demand across our ADHD portfolio, highlighted by record-high JORNAY PM prescriptions and prescriber adoption, alongside 41% revenue growth. Importantly, we have completed the acquisition of AZSTARYS and our integration is progressing well, with our expanded salesforce fully trained and deployed ahead of the important back-to-school season,” said Vikram Karnani, President and Chief Executive Officer. “In addition, our pain portfolio continues to provide a solid base for our business despite increased pressure on Nucynta franchise revenues. Together, our differentiated ADHD portfolio and established pain business provide a strong foundation for growth and long-term value creation. As we move into the second half of the year, we are focused on three key strategic priorities: driving growth in our ADHD business, maximizing the value of our pain portfolio, and strategically deploying capital to create long-term shareholder value." "During the quarter, we delivered solid performance across our business, successfully integrated AZSTARYS and generated robust operating cash flows," said Colleen Tupper, Chief Financial Officer. "As we enter the back-to-school season, our organization is well positioned with two differentiated and complementary ADHD medicines and supported by a single commercial platform that enhances our ability to serve healthcare providers and patients, alike.” ADHD Business Highlights Generated JORNAY PM net revenue of $46.1 million, up 41% year-over-year in the in the quarter ended June 30, 2026 (the 2026 Quarter). JORNAY PM prescribers reached an all-time high in the 2026 Quarter with over 30,000 healthcare providers writing JORNAY PM prescriptions, up 17.6% year-over-year. Grew JORNAY PM prescriptions 13.1% year over year in the 2026 Quarter. In May, completed the acquisition of AZSTARYS from Corium Therapeutics. The acquisition adds a highly complementary and differentiated ADHD medicine with significant growth potential and expected patent protection through 2037. Generated $12.9 million in AZSTARYS net revenue from May 12, 2026, to June 30, 2026, following the acquisition close. AZSTARYS prescriptions grew 1.9% in the 2026 Quarter compared to the quarter ended June 30, 2025 (the 2025) Quarter. In May, reinforced commitment to scientific research through published studies and poster presentations at leading medical conferences highlighting real-world data for JORNAY PM and AZSTARYS. Pain Portfolio Highlights Generated pain portfolio net revenues of $140.9 million in the 2026 Quarter, down 9% year-over-year. Generated Belbuca ® net revenue of $57.7 million in the 2026 Quarter, up 10% year-over-year. Generated Xtampza ® ER net revenue of $45.0 million in the 2026 Quarter, down 14% year-over-year. Generated Nucynta Franchise net revenue of $35.2 million in the 2026 Quarter, down 24% year-over-year. This included $5.1 million from the sale of the authorized generic (AG) versions of Nucynta and Nucynta ER. Corporate Updates In July, announced plans to relocate its corporate headquarters to downtown Boston in the first quarter of 2027. In June, recognized by the Boston Business Journal as one of the 2026 Best Places to Work in Massachusetts and named a USA Today Top Workplace for 2026. In May, strengthened its Board of Directors with the appointment of Michael Donovan, former senior audit partner at Ernst and Young (EY). Upcoming Events The Company will participate in the following upcoming investor conferences in the third quarter of 2026: Citi 2026 Biopharma Back to School Conference – New York, NY; September 9, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY; September 15, 2026 H.C. Wainwright 28th Annual Global Investment Conference – New York, NY; September 16, 2026 Financial Guidance for 2026 Collegium reaffirms its full-year 2026 guidance for JORNAY PM and raises AZSTARYS Revenue, Net and updates its full-year 2026 guidance for Product Revenues, Net, and Adjusted EBITDA. The decreases in Product Revenues, Net and Adjusted EBITDA are largely driven by lower-than-expected revenue from the AG versions of Nucynta and Nucynta ER due to lower net pricing. Prior Updated Product Revenues, Net $865 to $895 million $825 to $855 million JORNAY PM Revenue, Net $190 to $200 million Unchanged AZSTARYS Revenue, Net $60 to $70 million $65 to $75 million Adjusted EBITDA $475 to $500 million $445 to $470 million Financial Results for Quarter Ended June 30, 2026 Product revenues, net were $199.9 million for the 2026 Quarter, compared to $188.0 million for the quarter ended June 30, 2025 (the 2025 Quarter), representing a 6% increase year-over-year. GAAP operating expenses were $106.6 million for the 2026 Quarter, compared to $73.3 million for the 2025 Quarter, representing a 45% increase year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and acquisition related expenses were $66.6 million for the 2026 Quarter, compared to $61.9 million for the 2025 Quarter, representing an 8% increase year-over-year. GAAP net loss for the 2026 Quarter was ($15.1) million, with ($0.46) GAAP loss per share (basic) and ($0.46) GAAP loss per share (diluted), compared to GAAP net income for the 2025 Quarter of $12.0 million, with $0.38 GAAP earnings per share (basic) and $0.34 GAAP earnings per share (diluted). Non-GAAP adjusted net income for the 2026 Quarter was $75.4 million, with $1.92 adjusted earnings per share, compared to non-GAAP adjusted net income for the 2025 Quarter of $64.3 million, with $1.68 adjusted earnings per share. Adjusted EBITDA for the 2026 Quarter was $113.8 million, compared to $105.1 million for the 2025 Quarter, representing an 8% increase year-over-year. The Company generated $71.3 million in cash from operations, and exited the 2026 Quarter with cash, cash equivalents and marketable securities of $129.5 million. Conference Call Information The Company will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:00 a.m. ET. To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Second Quarter 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event. About Collegium Pharmaceutical, Inc. Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. With a portfolio of differentiated ADHD medications, anchored by JORNAY PM ® (methylphenidate HCl) and AZSTARYS ® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn . Non-GAAP Financial Measures To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management. In this press release we discuss the following financial measures that are not calculated in accordance with GAAP. Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as: adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs; adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes; adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments; we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position; we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA; we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business; we exclude litigation settlements and contingencies that are subject to recovery from adjusted EBITDA, as well as any applicable income items, credit adjustments, or recoveries due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred; we exclude acquisition-related expenses as these expenses would not have otherwise been incurred in the periods presented as part of our continuing operations and their exclusion is useful to investors because it enhances comparability of operating performance across periods. Acquisition-related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, legal defense expenses for specific acquired claims that relate to acts that occurred prior to our acquisition, and miscellaneous other acquisition-related expenses incurred; we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business; we exclude changes in the fair value of contingent consideration, which are non-cash, acquisition-related items that are not part of our underlying business; we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; we exclude executive transition expenses from adjusted EBITDA as the amount and/or frequency of these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis; and we exclude other expenses, from time to time, that are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis. The Company has not provided a reconciliation of its full-year 2026 guidance for adjusted EBITDA to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expenses, amortization of acquired intangible assets, and changes in fair value of contingent consideration. These items are uncertain and depend on various factors that are outside of the Company’s control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, projected financial performance, including expected revenue and adjusted EBITDA; statements related to the anticipated benefits of the acquisition of AZSTARYS, including its impact on Collegium’s ADHD portfolio and commercial strategy; statements related to current and future market opportunities for our products and our assumptions related thereto and other statements that are not historic facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: our ability to realize the anticipated benefits of the AZSTARYS acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; significant transaction costs or the acquisition of unknown liabilities; future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenues, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Investor Contact: Ian Karp Head of Investor Relations ir@collegiumpharma.com Media Contact: Jessica Cotrone Senior Vice President, Corporate Communications & Corporate Affairs communications@collegiumpharma.com Collegium Pharmaceutical, Inc. Unaudited Selected Consolidated Balance Sheet Information (in thousands) June 30, December 31, 2026 2025 Cash and cash equivalents $ 129,467 $ 231,252 Marketable securities — 155,427 Accounts receivable, net 285,102 211,328 Inventory 113,269 40,912 Prepaid expenses and other current assets 60,326 32,642 Property and equipment, net 10,653 12,013 Operating lease assets 3,791 4,187 Intangible assets, net 1,186,084 669,510 Restricted cash 20,910 20,906 Deferred tax assets 120,774 112,539 Other noncurrent assets 15,237 20,193 Goodwill 190,177 145,925 Total assets $ 2,135,790 $ 1,656,834 Accounts payable and accrued liabilities $ 80,491 $ 73,123 Accrued rebates, returns and discounts 406,854 318,266 Business combination consideration payable 29,719 17,565 Term notes payable 852,824 571,112 Convertible senior notes 238,733 238,213 Operating lease liabilities 4,968 5,539 Deferred royalty obligation 121,357 121,563 Deferred revenue 9,445 9,778 Contingent consideration 38,525 — Deferred tax liabilities 40,965 — Shareholders’ equity 311,909 301,675 Total liabilities and shareholders’ equity $ 2,135,790 $ 1,656,834 Collegium Pharmaceutical, Inc. Unaudited Condensed Statements of Operations (in thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Product revenues, net $ 199,878 $ 188,000 $ 393,398 $ 365,757 Cost of product revenues Cost of product revenues (excluding intangible asset amortization) 26,633 24,143 47,434 49,103 Intangible asset amortization 62,953 55,473 118,426 110,946 Total cost of product revenues 89,586 79,616 165,860 160,049 Gross profit 110,292 108,384 227,538 205,708 Operating expenses Selling, general and administrative 106,594 73,637 192,944 150,060 Gain on fair value remeasurement of contingent consideration — (358 ) — (1,144 ) Total operating expenses 106,594 73,279 192,944 148,916 Income from operations 3,698 35,105 34,594 56,792 Interest expense (19,519 ) (20,463 ) (35,381 ) (41,253 ) Interest income 2,289 2,383 5,995 4,608 (Loss) income before income taxes (13,532 ) 17,025 5,208 20,147 Provision for income taxes 1,519 5,042 5,763 5,747 Net (loss) income $ (15,051 ) $ 11,983 $ (555 ) $ 14,400 (Loss) earnings per share — basic $ (0.46 ) $ 0.38 $ (0.02 ) $ 0.45 Weighted-average shares — basic 32,460,783 31,810,612 32,275,159 31,802,222 (Loss) earnings per share — diluted $ (0.46 ) $ 0.34 $ (0.02 ) $ 0.44 Weighted-average shares — diluted 32,460,783 39,075,703 32,275,159 39,283,297 Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 GAAP net (loss) income $ (15,051 ) $ 11,983 $ (555 ) $ 14,400 Adjustments: Interest expense 19,519 20,463 35,381 41,253 Interest income (2,289 ) (2,383 ) (5,995 ) (4,608 ) Provision for income taxes 1,519 5,042 5,763 5,747 Depreciation 1,812 1,135 2,275 2,226 Amortization 62,953 55,473 118,426 110,946 Stock-based compensation 14,484 10,818 25,364 22,342 Recognition of step-up basis in inventory 5,417 1,954 5,417 5,431 Executive transition expense 1,393 — 1,393 1,397 Acquisition-related expenses 24,086 935 30,261 2,224 Gain on fair value remeasurement of contingent consideration — (358 ) — (1,144 ) Total adjustments $ 128,894 $ 93,079 $ 218,285 $ 185,814 Adjusted EBITDA $ 113,843 $ 105,062 $ 217,730 $ 200,214 Collegium Pharmaceutical, Inc. Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 GAAP operating expenses $ 106,594 $ 73,279 $ 192,944 $ 148,916 Adjustments: Stock-based compensation 14,484 10,818 25,364 22,342 Executive transition expense 1,393 — 1,393 1,397 Acquisition-related expenses 24,086 935 30,261 2,224 Gain on fair value remeasurement of contingent consideration — (358 ) — (1,144 ) Total adjustments $ 39,963 $ 11,395 $ 57,018 $ 24,819 Adjusted operating expenses $ 66,631 $ 61,884 $ 135,926 $ 124,097 Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 GAAP net (loss) income $ (15,051 ) $ 11,983 $ (555 ) $ 14,400 Adjustments: Non-cash interest expense 1,082 1,355 1,901 2,722 Amortization 62,953 55,473 118,426 110,946 Stock-based compensation 14,484 10,818 25,364 22,342 Recognition of step-up basis in inventory 5,417 1,954 5,417 5,431 Executive transition expense 1,393 — 1,393 1,397 Acquisition-related expenses 24,086 935 30,261 2,224 Gain on fair value remeasurement of contingent consideration — (358 ) — (1,144 ) Income tax effect of above adjustments (1) (18,959 ) (17,871 ) (37,588 ) (36,608 ) Total adjustments $ 90,456 $ 52,306 $ 145,174 $ 107,310 Non-GAAP adjusted net income $ 75,405 $ 64,289 $ 144,619 $ 121,710 Adjusted weighted-average shares — diluted (2) 39,935,892 39,075,703 40,076,322 39,283,297 Adjusted earnings per share (2) $ 1.92 $ 1.68 $ 3.67 $ 3.16 (1) The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended June 30, 2026 and 2025 were 22.9% and 25.7%, respectively; and the blended federal and state statutory rate for the six months ended June 30, 2026 and 2025 were 23.6% and 25.8%, respectively. As such, the non-GAAP effective tax rates for the three months ended June 30, 2026 and 2025 were 17.3% and 25.5%, respectively; and the non-GAAP effective tax rates for the six months ended June 30, 2026 and 2025 were 20.6% and 25.4%, respectively. (2) Adjusted weighted-average shares - diluted were calculated using the “if-converted” method for our convertible notes in accordance with ASC 260, Earnings per Share . As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense is added-back to non-GAAP adjusted net income. For the three and six months ended June 30, 2026 and 2025, adjusted weighted-average shares – diluted includes 6,606,305 shares attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive.